Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Oct 16

PMID 30319966

Citations 12

Authors

Vincenzo Di Nunno

Lidia Gatto

Matteo Santoni

Alessia Cimadamore

Antonio Lopez-Beltran

Liang Cheng

Marina Scarpelli

Rodolfo Montironi

Francesco Massari

Affiliations

Soon will be listed here.

Abstract

Management of localized and advanced prostate cancer benefits from several therapeutic options with a surprising improvement in terms of clinical outcome. The selection of patients more likely to benefit from a specific approach still remains a key issue as well as the early identification of patients with aggressive disease which could benefit from a more aggressive treatment strategy. The lack of reliable bio-marker in castration resistant setting able to monitor response to treatment and early inform about tumor progression is an emerging issue. Accordingly, circulating DNA and circulating tumor cells appears a promising and attractive approach despite to date practical applications of these techniques are few and not validated. The aim of this review of the literature is to explore current knowledge on liquid biopsy in prostate cancer focusing on possible future applications.

Citing Articles

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends.

Figueiredo A, Costa L, Mauricio M, Figueira L, Ramos R, Martins-da-Silva C Clin Drug Investig. 2022; 42(8):631-642.

PMID: 35829924 PMC: 9338100. DOI: 10.1007/s40261-022-01178-y.

Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer.

Chauhan G, Heemers H Cancers (Basel). 2021; 13(16).

PMID: 34439101 PMC: 8393938. DOI: 10.3390/cancers13163947.

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.

Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C Int J Mol Sci. 2021; 22(11).

PMID: 34073818 PMC: 8197269. DOI: 10.3390/ijms22115522.

Treatment and trials in non-metastatic castration-resistant prostate cancer.

Lokeshwar S, Klaassen Z, Saad F Nat Rev Urol. 2021; 18(7):433-442.

PMID: 34002069 DOI: 10.1038/s41585-021-00470-4.

Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer.

Greene J, Baird A, Lim M, Flynn J, McNevin C, Brady L Front Cell Dev Biol. 2021; 9:605686.

PMID: 33718350 PMC: 7946979. DOI: 10.3389/fcell.2021.605686.

References

Jiang R, Lu Y, Ho H, Li B, Chen J, Lin M . A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget. 2015; 6(42):44781-93. PMC: 4792591. DOI: 10.18632/oncotarget.6330. View

Miyamoto D, Lee R, Stott S, Ting D, Wittner B, Ulman M . Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012; 2(11):995-1003. PMC: 3508523. DOI: 10.1158/2159-8290.CD-12-0222. View

Stone L . Prostate cancer: Mastering transcription: TMPRSS2-ERG and the cis-regulatory landscape. Nat Rev Urol. 2017; 14(10):579. DOI: 10.1038/nrurol.2017.141. View

Olmos D, Arkenau H, Ang J, Ledaki I, Attard G, Carden C . Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2008; 20(1):27-33. DOI: 10.1093/annonc/mdn544. View

Cerrato A, Morra F, Celetti A . Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res. 2016; 35(1):179. PMC: 5123312. DOI: 10.1186/s13046-016-0456-2. View

Anderson P, McKissic S, Logan M, Roh M, Franco O, Wang J . Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest. 2012; 122(5):1907-19. PMC: 3336973. DOI: 10.1172/JCI58540. View

Kirschner A, Wang J, van der Meer R, Anderson P, Franco-Coronel O, Kushner M . PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 2014; 107(2). PMC: 4326311. DOI: 10.1093/jnci/dju407. View

Lohr J, Adalsteinsson V, Cibulskis K, Choudhury A, Rosenberg M, Cruz-Gordillo P . Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014; 32(5):479-84. PMC: 4034575. DOI: 10.1038/nbt.2892. View

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Nakazawa M . Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015; 1(5):582-91. PMC: 4537351. DOI: 10.1001/jamaoncol.2015.1341. View

10.

Samson D, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen P, Bennett C . Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002; 95(2):361-76. DOI: 10.1002/cncr.10647. View

11.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

12.

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

13.

Aparicio A, Harzstark A, Corn P, Wen S, Araujo J, Tu S . Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19(13):3621-30. PMC: 3699964. DOI: 10.1158/1078-0432.CCR-12-3791. View

14.

de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A . Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res. 2018; 25(3):928-936. DOI: 10.1158/1078-0432.CCR-18-0981. View

15.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

16.

Vagner T, Spinelli C, Minciacchi V, Balaj L, Zandian M, Conley A . Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018; 7(1):1505403. PMC: 6084494. DOI: 10.1080/20013078.2018.1505403. View

17.

Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V . Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat Rev. 2017; 54:68-73. DOI: 10.1016/j.ctrv.2017.02.001. View

18.

Danila D, Anand A, Schultz N, Heller G, Wan M, Sung C . Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol. 2013; 65(6):1191-7. PMC: 4113474. DOI: 10.1016/j.eururo.2013.07.006. View

19.

Bill-Axelson A, Holmberg L, Garmo H, Rider J, Taari K, Busch C . Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370(10):932-42. PMC: 4118145. DOI: 10.1056/NEJMoa1311593. View

20.

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View